The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the supplemental new drug ...

The agency turned back Astellas’ attempt to update its drug Izervay’s labeling. Elsewhere, former NCI director Ned Sharpless ...

Investing.com - Shares of biopharmaceutical firm Apellis Pharmaceuticals Inc (NASDAQ: APLS) surged 16.44% to $31 on Tuesday ...

Belite Bio's, Tinlarebant, targets eye diseases STGD1 and GA, showing promising results but with delayed phase 3 trial data.

The FDA has denied Astellas’ attempt to bolster the label for its vision loss treatment Izervay with additional two-year data ...

The FDA rejected an application from Astellas seeking to change the prescribing label for its eye drug Izervay to allow less ...

Jefferies analyst Akash Tewari maintained a Buy rating on Apellis Pharmaceuticals (APLS – Research Report) today and set a price target of ...

Cases of several dangerous bacterial infections and viruses have been growing around the U.S. CBS News medical contributor Dr ...

Aclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...

Trump Defies the #MeToo Movement With Cabinet Picks Facing Accusations Donald Trump, who was found liable for sexual abuse last year, appears determined to force a fight over the role of such ...

Stewart-Haas' sad demise belies its legacy of unlikely success (October 31, 2024, 7:00 PM ET) ...

Covering Netflix News Independently Since 2013. What’s on Netflix is not owned by or affiliated with Netflix or any of its partners in any capacity. The authors of this site also have no affiliation ...